Marcain Adrenalin

Bupivacaine hydrochloride, the active ingredient in Marcain Adrenalin, is a local anesthetic (amide) presented as a solution for epidural and infiltration use. It provides regional anesthesia for surgical procedures, epidural analgesia, and infiltration anesthesia in adult patients. GNH USA supplies Marcain Adrenalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Marcain Adrenalin is a local anesthetic that acts on peripheral nerves to produce reversible loss of sensation for surgical and pain‑control applications. - Regional anesthesia for surgical procedures: delivers prolonged numbness of the operative area. - Epidural analgesia: provides continuous pain relief during labor or postoperative periods. - Infiltration anesthesia: allows localized numbing of tissues for minor procedures.

Adverse reactions may occur following administration of Marcain Adrenalin.

Common Side Effects: - Transient pain or burning at the injection site. - Mild hypotension. - Bradycardia. - Nausea.

Serious or Rare Side Effects: - Cardiac arrhythmias, including ventricular tachycardia. - Central nervous system seizures. - Methemoglobinemia, a rare blood disorder.

Careful assessment and monitoring are required when using Marcain Adrenalin. - Cardiac history assessment: evaluate risk of arrhythmias before administration. - Avoid intravascular injection: aspirate prior to injection to prevent systemic toxicity. - Use lowest effective concentration: limit total dose to reduce toxicity. - Monitor fetal status in obstetric use: safety in pregnancy is not established. - Allergy check: discontinue if patient shows hypersensitivity to amide anesthetics. - Store at ambient temperature: keep in original container, protect from light and moisture.

Potential drug interactions should be reviewed before prescribing Marcain Adrenalin.

Major Interactions (Avoid): - Other local anesthetics: additive neuro‑cardiac toxicity. - Class I antiarrhythmic agents (e.g., quinidine): increased risk of cardiac arrhythmias. - Beta‑blockers: may potentiate bradycardia.

Moderate Interactions (Monitor Closely): - MAO inhibitors: possible prolonged hypotension. - CYP3A4 inhibitors (e.g., erythromycin): may raise bupivacaine plasma levels. - Non‑steroidal anti‑inflammatory drugs: may affect platelet function and increase bleeding risk.